Treating fibromyalgia alongside IBS: a small and mixed evidence base
A small review reported lower pain scores with some medicines, mixed dietary results and no statistically significant probiotic benefit over placebo.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reported lower pain scores with cyclobenzaprine and pregabalin, mixed dietary findings, and no statistically significant probiotic benefit over placebo. These findings concern people with both fibromyalgia and IBS. The abstract does not quantify benefits or harms, and a nonsignificant probiotic result does not establish that probiotics have no effect.
Only a small trial set contributed to the pooled analysis. The abstract omits treatment durations, drug comparators and numerical benefit or harm estimates, limiting assessment of clinical importance and durability.
Which outcomes were considered
The review covered oral medicines, dietary changes and probiotics. It sought evidence on pain, overall well-being, depressive symptoms, quality of life and safety, although the abstract mainly describes pain and tolerability findings.
What the safety summary leaves out
The greatest adverse-effect burden was reported in the cyclobenzaprine 30 mg group. Other interventions were described as generally tolerated, but the abstract gives no event rates or severity breakdown to assess those differences.
The original publication
Efficacy and safety of interventions for Fibromyalgia syndrome comorbid with Irritable bowel syndrome: systematic review.
Elkalla MA, Ali YG, Ewais MM et al.
Clin Rheumatol · 2026
- PubMed ID
- 41423615
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.